Business Context and Reporting Period
Company: Dyadic International, Inc. (DYAI)
Filing Type: Form 8-K (Current Report)
Date of Report: March 27, 2026
Principal Office: Jupiter, FL
Listing: The Nasdaq Stock Market LLC (Nasdaq Capital Market)
Key Financial Metrics
This filing does not report specific revenue, profit, cash flow, or debt figures. The report focuses on regulatory compliance thresholds rather than operational financial performance.
- Stockholders' Equity Requirement: $2.5 million (Company is currently out of compliance).
- Market Value Requirement: $35 million (Company is currently out of compliance).
- Net Income Requirement: $500,000 from continuing operations (Company is currently out of compliance).
- Minimum Bid Price: $1.00 (Company remains out of compliance with this separate requirement).
Material Changes and Events
On March 27, 2026, the Company received a deficiency notice from Nasdaq regarding non-compliance with Nasdaq Listing Rule 5550(b) (Continued Listing Requirement). The Company failed to meet at least one of the three minimum requirements for continued listing: stockholders' equity, market value of listed securities, or net income.
Additionally, the Company remains out of compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), with a separate deadline to regain compliance by June 17, 2026.
Outlook, Management Commentary, and Risks
Management Plan: The Company intends to actively monitor compliance and evaluate options to resolve the deficiency, likely targeting the $2.5 million stockholders' equity requirement.
Timeline:
- Plan Submission Deadline: May 11, 2026 (45 calendar days from notice).
- Potential Cure Period: Up to 180 days (until September 23, 2026) if the plan is accepted.
- Appeal Option: If the plan is not accepted, the Company may appeal to a hearings panel, though success is not assured.
Risks and Contingencies:
- Failure to cure either deficiency by the applicable deadline could result in delisting.
- Forward-looking statements are subject to risks including a history of net losses, capital needs, failure to commercialize microbial protein platforms, and regulatory acceptance.
Investor Verification Checklist
- Verify the Company's current stockholders' equity balance to assess feasibility of meeting the $2.5 million threshold.
- Monitor the Company's stock price to determine if it meets the $1.00 minimum bid price requirement by June 17, 2026.
- Review the plan to be submitted by May 11, 2026, for specific strategies to regain compliance.
- Check for any subsequent filings regarding the acceptance or rejection of the compliance plan by Nasdaq.
- Assess the Company's capital needs and funding availability given the history of net losses.